Jonathan Hopper
Founder & Vice President - Platforms OMass Therapeutics
Jonathan Hopper is Vice President, Platforms and founder of OMass Therapeutics. Jonathan completed his PhD in native mass spectrometry under the supervision of Prof. Neil Oldham and moved to the University of Oxford to develop native mass spectrometry approaches for studying membrane proteins with Professor Dame Carol Robinson. His research was focussed on developing technologies which enable or improve the structural/functional information obtained on challenging membrane protein assemblies and drug targets. He founded OMass and served as the first Chief Executive Officer, leading the company through its seed funding and series A financing rounds, allowing OMass to develop its own drug discovery programmes in-house.
Seminars
- Explore why complex, dynamic, and previously inaccessible targets have challenged traditional drug discovery approaches
- Discover how advances in structural biology, biophysics, computational chemistry, and AI are expanding the druggable proteome
- Understand how molecular glues, degraders, and other emerging modalities reshaping discovery portfolios are and required capabilities
- Identify which technologies are driving value today versus those likely to transform discovery over the next decade
- Learn how leading organisations are combining experimental and computational approaches to pursue challenging targets with greater confidence
- Understand how native mass spectrometry can reveal biologically relevant protein conformations and interactions that are difficult to capture using a single technique
- Learn how to integrate structural biology, biophysics, and high-resolution structural data to generate actionable hypotheses for hit identification and optimisation
- Explore case studies from challenging target classes, including the TNF superfamily, where combining orthogonal technologies enabled tractable drug discovery strategies
